| Literature DB >> 35837350 |
Susanne Schiek1,2, Thilo Bertsche1,2, Ines Wakob1,2, Gordian Lukas Schmid3, Ingo Nöhring3, Romy Elze4, Ralf Sultzer5, Thomas Frese6.
Abstract
Purpose: Mobile health (mHealth) applications offer structured and timely communication between patients and general practitioners (GPs) about adverse drug reactions (ADR). Preconditions, functionalities and barriers should be studied to ensure safe implementation.Entities:
Keywords: adverse drug reaction; general practitioner; mHealth; patient; questionnaire survey
Year: 2022 PMID: 35837350 PMCID: PMC9275429 DOI: 10.2147/JMDH.S369625
Source DB: PubMed Journal: J Multidiscip Healthc ISSN: 1178-2390
Figure 1Flow chart descriptive of study population at patient level.
Characteristics of Participants; GP: General Practitioner
| Characteristics of the Participating General Practices [n (%)] | Total: 20 (100%) |
|---|---|
| Included patients per general practice [Median (Q25/Q75; Min-Max)] | 21 (16/33;11–50) |
| Included GPs per general practice [Median (Q25/Q75; Min-Max)] | 1 (1/2; 1–3) |
| Duration of survey conduction in hours [Median (Q25/Q75; Min-Max)] | 5 (4/6; 3.5–8) |
| Localization of the general practice | |
| Urban [n (%)] | 14 (70%) |
| Rural [n (%)] | 6 (30%) |
| Gender | |
| Female [n (%)] | 21 (68%) |
| Male [n (%)] | 9 (29%) |
| Not specified [n (%)] | 1 (3%) |
| Age in years [Median (Q25/Q75; Min-Max)] | 43 (38/56; 33–72) |
| Not specified [n (%)] | 1 (3%) |
| Professional experience in years [Median (Q25/Q75; Min-Max)] | 14 (11/28; 1–46) |
| Not specified or not classifiable [n (%)] | 4 (13%) |
| Gender | |
| Female [n (%)] | 272 (57%) |
| Male [n (%)] | 183 (38%) |
| Not specified [n (%)] | 25 (5%) |
| Age in years [Median (Q25/Q75; Min-Max)] | 47 (31/65.5; 15–91) |
| Not specified [n (%)] | 41 (9%) |
Figure 2(A) Patients’ willingness to use an mHealth application for ADR communication, depending on their age. Question to patient: “Would you use an app as described to report ADRs to your GP?” Values refer to the relative number of patients answering yes (dark grey), rather yes (light grey), rather no (light grey-hatched), no (dark grey-hatched); answers not specified or not classifiable (black). n=41 patients did not specify age and, therefore, are not represented in the Figure. (B) GPs’ willingness to use an mHealth application for ADR communication, depending on their age. Question to GP: “Would you use a software as described?” Values refer to the relative number of GPs answering yes (dark grey), rather yes (light grey), rather no (light grey-hatched), no (dark grey-hatched); answers not specified or not classifiable (black). n=1 GP did not specify age and, therefore, is not represented in the Figure. The remaining age groups compared to (A) result with n=0 each.
Figure 3Question to GP: “How useful do you rate the support of the mHealth technology in managing ADRs in your patients … [with the following concrete possible functionalities]”. Questions to patient: “In what cases would you rate the app as useful?” Alternative questions, concerning functionalities patients might have trouble with to assess its “usefulness” due to the pretest: “Would you be willing to use the app to … ”. The difficulties to rate “usefulness” are related to the layperson’s limited ability to recognize the relevance of the information in relation to the evaluation of the ADR and its causality. *Patients were asked about their willingness to supply the information.
Aspects of Patients’ Preconditions and Users’ Assessment of Possible Functionalities for Realization of an mHealth Application for ADR Communication; Closed Questions (Answers Presented as Likert Scales or Categorical Items); Number of Responses in % Based on the Number of Participating Patients (n=480; n=378a)
| Questions to the Patient | n (%) |
|---|---|
| Have you previously experienced any uncertainty with newly prescribed Medication? (Precondition) | |
| Yes; Rather yes | 63 (13%); 74 (15%) |
| No; Rather no | 174 (36%); 118 (25%) |
| Not specified or not classifiable | 51 (11%) |
| Will your GP be easy to contact, if you do not tolerate a newly prescribed medication? (Precondition) | |
| Yes; Rather yes | 281 (59%); 114 (24%) |
| No; Rather no | 7 (1%); 21 (4%) |
| Not specified or not classifiable | 57 (12%) |
| Would you prefer to select ADRs from a prepared list or to describe them in your own words when reporting ADRs via app to your GP?1 (Procedural functionality) | |
| Selected from a prepared drug specific list | 87 (23%) |
| Described in own words | 94 (25%) |
| Both options | 163 (43%) |
| Not specified or not classifiable | 34 (9%) |
| Reporting side effects via app weekly is … 1 (Procedural functionality) | |
| Too frequent | 156 (41%) |
| Just right | 137 (36%) |
| Too rare | 35 (9%) |
| Not specified or not classifiable | 50 (13%) |
Note: aBasic knowledge regarding mHealth applications was necessary so that a filter question was used (“Can you imagine anything under the term ‘app’?”) and calculation was based on a population of n=378 patients, who answered this question with “yes”.
Aspects of General Practitioners’ (GP) Preconditions and Utility Assessment for Realization of an mHealth Application for ADR Communication. Closed Questions (Answers Rated on Likert Scales or as Categorical Items); Number of Responses in % Based on the Number of Participating GPs (n=31)
| Questions to the GP | n (%) |
|---|---|
| In your opinion, in which situations does it make sense to ask patients ADRs? (multiple answers possible) (Precondition) | |
| When new therapies are started | 15 (48%) |
| When therapies are changed | 15 (48%) |
| For nursing home patients/in home care | 11 (35%) |
| When it’s difficult for the patient to reach the general practice | 10 (32%) |
| When certain drugs have been prescribed | 8 (26%) |
| In long term therapy | 6 (19%) |
| Does not make sense in any situation | 8 (26%) |
| Should the patient select ADRs from a prepared medication-specific list or describe them in his own words when reporting ADRs via app? (Procedural functionality) | |
| Selected from a prepared drug specific list | 12 (39%) |
| Described in own words | 9 (29%) |
| Both options | 6 (19%) |
| Not specified or not classifiable | 4 (13%) |
| How should reports of ADRs be transferred from patient to GP? (multiple answers possible) (Procedural functionality) | |
| Prioritized by urgency | 18 (58%) |
| Bundled once a day at a freely selectable time | 13 (42%) |
| Individually, immediately after the patient entered the information | 5 (16%) |
| Bundled when a certain number of side effects reports is reached | 2 (6%) |
| Others (individual contact) | 2 (6%) |
Abbreviation: ADR, adverse drug reaction.
Barriers to Use mHealth Technology in ADR Communication and Future Challenges. Answers to Open Question Were Categorized; Answers Mentioned Only Once are Subsumed in “Others”; Number of Responses in % Based on the Number of Participating Patients (n=480) and General Practitioners (GPs; n=31)
| Barriers to a ADRs mHealth technology (patients, “What are reasons against using an app – as described – to report ADRs of your medication to your GP?” | npatient with free text entry (%) |
| Personal GP contact preferred | 31 (6%) |
| Data privacy concerns | 12 (3%) |
| Lack of technical affinity | 11 (2%) |
| No necessity | 7 (1%) |
| Doubts about practicability | 5 (1%) |
| Too much effort | 4 (1%) |
| Enhanced risk of nocebo effect | 2 (<1%) |
| Others (Security concerns, Too much attention on the disease) | 2 (<1%) |
| Unspecified | 4 (1%) |
| Future challenges for a ADRs mHealth technology (patients, “What else would be important to you in such an app?” | npatient with free text entry (%) |
| Easy handling | 20 (4%) |
| Provision of drug-related information | 16 (3%) |
| Communication with GP | 15 (3%) |
| Drug-drug interaction check | 14 (3%) |
| Data protection | 11 (2%) |
| Adherence support | 11 (2%) |
| Information on other drugs with the same ingredient and alternative therapy options | 7 (1%) |
| Monitoring of specific parameters and effectiveness | 6 (1%) |
| Other supplementary functions (digital organ donor card, fitness check, list of specialists, reading of customers rating) | 4 (1%) |
| Comprehensibility | 3 (1%) |
| Emergency pass function | 2 (<1%) |
| Others (actuality, free use, limitation to therapy change, low battery drain) | 4 (1%) |
| Unspecified | 5 (1%) |
| Future challenges for an ADR mHealth technology (GPs, “What further requirements would you place on such a software in order that it can be integrated into your everyday practice and support you in the therapy of your patients?” | nGP with free text entry (%) |
| Uncomplicated use with low expenditure of time and personnel | 6 (19%) |
| Integration into office software | 5 (16%) |
| Customized to requirements | 2 (6%) |
| Necessity | 2 (6%) |
| Security | 2 (6%) |
| Others (data protection, lay comprehensibility, limitation to rarely used drugs, ongoing maintenance, availability of mobile electronic device) | 5 (16%) |
| Unspecified | 1 (3%) |